Abstract
Single agent immune checkpoint inhibitors are largely ineffective in treating recurrent ovarian cancer (OC). In a recently completed phase 2 clinical trial at our institute (NCT02853318), we combined pembrolizumab with anti-VEGF bevacizumab and oral metronomic cyclophosphamide in patients with recurrent ovarian cancer. Our phase 2 trial had a median progression free survival (PFS) of 10.0 months and 25% of the recurrent OC patients had a PFS > 12 months with excellent quality of life. Based on the results of this trial, our center has been using this regimen off label in patients with recurrent gynecologic malignancies, given the limited efficacy of traditional second line chemotherapies in this patient population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
